Factors Associated With Fecal Microbiota Transplant Failure in the Treatment of Recurrent Clostridioides difficile Infection: A Single-Center Retrospective Study

被引:2
|
作者
Warraich, Fatima [1 ]
Sohail, Syed H. [1 ]
Knee, Alexander [2 ]
Smith, Jacob [3 ]
Schlecht, Hans [3 ]
Skiest, Daniel [3 ]
机构
[1] Univ Massachusetts, Internal Med, Chan Baystate Med Ctr, Springfield, MA 01199 USA
[2] Univ Massachusetts, Off Res Epidemiol Biostat Res Core, Chan Baystate Med Ctr, Springfield, MA USA
[3] Univ Massachusetts, Infect Dis, Dept Hematol Oncol, Chan Baystate Med Ctr, Springfield, MA USA
关键词
fmt failure; recurrent c diff; gut biome; fecal microbiota transplantation (fmt); clostridioides difficile infection; VANCOMYCIN;
D O I
10.7759/cureus.45118
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundClostridioides difficile infection (CDI) is a major cause of hospital-acquired diarrhea and is associated with substantial morbidity and mortality. Recurrences following treatment are common. Fecal microbiota transplantation (FMT) is a therapeutic intervention in which stool from a healthy donor is administered to a patient with recurrent CDI. Studies to date of predictors of FMT failure have primarily included inpatients. In this study, we aimed to describe FMT failure rates within one year of FMT and evaluate factors associated with FMT failure.MethodologyWe conducted an exploratory retrospective study of consecutive patients who underwent outpatient FMT at a single tertiary care center in Western Massachusetts from December 2014 through September 2018. We collected patient data including demographics, CDI-related factors, and FMT-related factors. FMT failure was defined as non-response or recurrence of diarrhea, associated with positive stool C. difficile toxin or polymerase chain reaction. Unadjusted relative risk (RR) and 95% confidence intervals for factors associated with FMT failure were estimated using log-binomial regression. ResultsA total of 92 patients were included with a mean age of 64 years. CDI severity was mild or moderate in 73% and severe or fulminant in 27%. The most common FMT indication was recurrent CDI in 76% of patients. FMT failure occurred in 25 of 92 (27%) patients, with half occurring within 11 days. Factors associated with FMT failure were active malignancy (RR = 2.56), prior hospitalizations (RR = 2.42), and receipt of non-CDI antibiotics within six months of FMT (RR = 2.80). We did not observe strong associations for risk of FMT failure with age >= 65, sex, use of proton pump inhibitors or H2 receptor agonists, history of colectomy, immunosuppression, history of malignancy, diabetes, appendectomy, CDI severity, or probiotic use.ConclusionsActive malignancy, prior CDI hospitalizations, and non-CDI antibiotics within six months before FMT were associated with FMT failure in the outpatient setting. Knowledge of the above factors may help inform shared decision-making with patients at risk for FMT failure.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection
    Voth, Elida
    Khanna, Sahil
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (07) : 669 - 676
  • [2] Fecal microbiota transplantation for recurrent Clostridioides difficile infection
    Haber, Stacy L.
    Raney, Carrington R. K.
    Larson, Trent L.
    Lau, Jennifer Park
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (13) : 935 - 942
  • [3] Is a Single Fecal Microbiota Transplant a Promising Treatment for Recurrent Clostridium difficile Infection?
    Hota, Susy S.
    Poutanen, Susan M.
    OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (03):
  • [4] Predictors of Fecal Microbiota Transplant Failure in Clostridioides difficile Infection An Updated Meta-analysis
    Beran, Azizullah
    Sharma, Sachit
    Ghazaleh, Sami
    Lee-Smith, Wade
    Aziz, Muhammad
    Kamal, Faisal
    Acharya, Ashu
    Adler, Douglas G.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2023, 57 (04) : 389 - 399
  • [5] Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)
    Minkoff, Nathan Zev
    Aslam, Scheherzade
    Medina, Melissa
    Tanner-Smith, Emily E.
    Zackular, Joseph P.
    Acra, Sari
    Nicholson, Maribeth R.
    Imdad, Aamer
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (04):
  • [6] Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Clostridioides difficile Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis
    Shin, Jae Hyun
    Chaplin, Ashley S.
    Hays, R. Ann
    Kolling, Glynis L.
    Vance, Sheila
    Guerrant, Richard L.
    Archbald-Pannone, Laurie
    Warren, Cirle A.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07)
  • [7] A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection
    Wang, Yifan
    Hunt, Aaron
    Danziger, Larry
    Drwiega, Emily N.
    ANTIBIOTICS-BASEL, 2024, 13 (05):
  • [8] Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
    Yoon, Hyuk
    Shim, Hyun Ik
    Seol, Mijin
    Shin, Cheol Min
    Park, Young Soo
    Kim, Nayoung
    Lee, Dong Ho
    GUT AND LIVER, 2021, 15 (01) : 61 - 69
  • [9] A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection
    Drekonja, Dimitri M.
    Shaukat, Aasma
    Huang, Yuan
    Zhang, Jane H.
    Reinink, Andrew R.
    Nugent, Sean
    Dominitz, Jason A.
    Davis-Karim, Anne
    Gerding, Dale N.
    Kyriakides, Tassos C.
    CLINICAL INFECTIOUS DISEASES, 2024, 80 (01) : 52 - 60
  • [10] Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome
    Gotoh, Kazuyoshi
    Sakaguchi, Yoshihiko
    Kato, Haru
    Osaki, Hayato
    Jodai, Yasutaka
    Wakuda, Mitsutaka
    Take, Akira
    Hayashi, Shunji
    Morita, Eri
    Sugie, Takehiko
    Ito, Yoichiro
    Ohmiya, Naoki
    ANAEROBE, 2022, 73